Taken together, our immunological data indicate mobilization of CD8+ T cells, redistribution of tumor-reactive clones, and most importantly, prominent CD8+ T-cell influx into tumors of patients experiencing TIM-3 decrease, which was associated with the strongest survival benefit. This evidence concerns the gene CD8A and neoplasm.